Enveric’s Patent Win Targets New Frontiers in Sleep Medicine [Microdose]
Tuesday, June 3, 2025 1 min read
Key Takeaway: Enveric Biosciences has been granted U.S. Patent No. 12,187,679, which covers a new class of hydroxylated psilocybin derivatives. These derivatives selectively target melatonin MT1 receptors, which are crucial for regulating sleep-wake cycles and circadian rhythms. This patent strengthens Enveric's position in the neurotherapeutics field.
Price reaction · baseline $15.48 (2025-06-03T15:04:00.000Z) · hit during market hours · clean, no other ENVB news in the window
day 0 close · peak
-1.6%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric has secured a significant patent for neurotherapeutics.
The patent covers innovative psilocybin derivatives targeting sleep regulation.
This advancement positions Enveric as a leader in sleep medicine.
Full Press Release Details
With U.S. Patent No. 12,187,679 now granted, Enveric Biosciences has secured more than intellectual property—it’s staked a claim on the future of neurotherapeutics. The Cambridge-based biotech firm announced this week that its latest patent covers a class of hydroxylated psilocybin derivatives that selectively target melatonin MT1 receptors, key regulators of sleep-wake cycles and circadian rhythms.
Full Article >>
Frequently Asked Questions
What does Enveric's new patent cover?
The patent covers hydroxylated psilocybin derivatives targeting melatonin MT1 receptors.
Why are melatonin MT1 receptors important?
They are key regulators of sleep-wake cycles and circadian rhythms.
What is the significance of this patent for Enveric?
It strengthens Enveric's position in the neurotherapeutics market.